COVID-19 Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07WEV
|
|||
| Drug Name |
PMID26868298-compound-5705213
|
|||
| Synonyms |
PMID26868298-C-5705213
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Middle East Respiratory Syndrome (MERS) | Preclinical | [1], [2] | Severe acute respiratory syndrome (SARS) | Preclinical | [1], [2] |
| Therapeutic Class |
Antiviral Agents
|
|||
| Structure |
 |
Download2D MOL |
||
| Target | Top | |||
|---|---|---|---|---|
| Target(s) | HUMAN cathepsin L (CTSL) | Target Info | Blocker | [1], [2] |
| Compound 5705213 can inhibit cathepsin L which is involved in the endosomal pathway and block CoVs entry to exhibit broad-spectrum activities against enveloped RNA viruses such as CoVs (SARS-CoV, MERS-CoV). | ||||
| References | Top | |||
|---|---|---|---|---|
| 1 | Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. | |||
| 2 | Identification of a Broad-Spectrum Antiviral Small Molecule Against Severe Acute Respiratory Syndrome Coronavirus and Ebola, Hendra, and Nipah Viruses by Using a Novel High-Throughput Screening Assay. J Virol. 2014 Apr;88(8):4353-65. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.